Podcasts about Chief scientific officer

In this episode of the Scrum.org Community Podcast, host Dave West sits down with Tyson Bertmaring, Head of Partnership Success and Adrian Veres, Chief Scientific Officer from Dyno Therapeutics, a cutting-edge gene therapy startup. They share how Dyno applies the ideas of the Agile Product Operating Model (APOM) to complex scientific research—shifting from traditional structures to empowered, cross-functional teams aligned to clear goals.You will hear how Dyno integrates APOM principles such as product-centric team design, continuous planning, and aligned incentives to drive innovation in a high-stakes environment. The conversation highlights how adopting a product mindset, supported by an enabling organization, creates the conditions for focus, adaptability, and breakthrough scientific results. 

Today, you will hear information about testing your male partner with a relatively new test called SpermQT. This week, the Fertility Docs, Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center welcome a groundbreaking guest: Dr. Kristen Brogaard, Chief Scientific Officer and Founder of Path Fertility. Kristen joins the Docs to discuss SpermQT, one of the first major innovations in male fertility testing in years. SpermQT goes beyond a traditional semen analysis to assess sperm DNA and determine whether sperm is capable of fertilizing an egg. If the SpermQT test is abnormal, it strongly suggests that natural conception or IUI will likely fail, making IVF the recommended next step.Kristen shares how Path Fertility is conducting multiple studies to evaluate pregnancy outcomes when the SpermQT test is applied to men whose partners conceive naturally or through IUI and aims to track pregnancy through delivery. Future analysis in the IVF lab will evaluate fertilization and embryo development in men with normal versus abnormal testing. SpermQT is helping to redefine how we understand male fertility, challenging the outdated assumption that a normal semen analysis equals fertility. If you order the test the DISCOUNT CODE is FDU. ReceptivaDx sponsored this podcast.

Kiran Krishnan is a research microbiologist and Chief Scientific Officer at Just Thrive, with expertise in gut health, probiotics, and the human microbiome.15 Daily Steps to Lose Weight and Prevent Disease PDF: https://bit.ly/46XTn8f - Get my FREE eBook now!Subscribe to The Genius Life on YouTube! - http://youtube.com/maxlugavereWatch my new documentary Little Empty Boxes - https://www.maxlugavere.com/filmThis episode is proudly sponsored by:JustThrive makes high quality probiotics with mental health in mind. Get 20% your first 90 day bottle when you go to https://justthrivehealth.com/GENIUS and use code GENIUSLIFE at checkout!Struggling with diet culture confusion? Fay connects you with a registered dietitian—often for $0 with insurance. To create a personalized, evidence-based plan that actually works, head to FayNutrition.com/GENIUS.Pique makes quadruple toxin-screened, cold extracted, and uber-delicious matcha for an all-day energy boost without the jitters! Head to http://piquelife.com/genius for up to 15% off.BiOptimizers makes a magnesium mega-supplement containing 7 forms of magnesium. They also make great digestive support aids. Head to ⁠bioptimizers.com/genius⁠ and use code GENIUS10 for 10% off.Shopify makes it easy to accept payments, manage orders, and build relationships with customers (cha-ching!). Get everything you need to sell in person and online at http://shopify.com/genius and get a one-dollar-per-month trial period!

Ying Tam, Chief Scientific Officer at Acuitas Therapeutics, discusses the company's role in delivering the first personalized CRISPR gene editing treatment to an infant with CPS-1, achieving treatment in just six months from diagnosis. Tam shares insights on evolving lipid nanoparticle technology beyond COVID vaccines, including LNPs that allow for next-generation immune-targeting delivery that is 10x more potent, and progress in delivering genetic medicines to stem cells and solid tumors. He also addresses the challenges of repeat dosing, a new biodegradable LNP formulation, and expanding genetic medicine beyond the liver to treat blood disorders and cancer.

This episode of VHHA's Patients Come First podcast features Dr. Saul Karpen, Chief Scientific Officer of the Virginia Commonwealth University Stravitz-Sanyal Institute for Liver Disease and Metabolic Health and President-Elect of the American Association for the Study of Liver Disease. He joins us for a conversation about his work, new pediatric guidelines developed to detect a life-threatening liver disease in infants, and more. Send questions, comments, feedback, or guest suggestions to pcfpodcast@vhha.com or contact on X (Twitter) or Instagram using the #PatientsComeFirst hashtag.

As AI systems rapidly advance and enhance data processing, experts are taking note of their surprising capabilities. But what does this sudden explosion of AI mean for modern society? What vulnerabilities should we be watching for? Dr. Matthew Lungren joins the podcast to shed light on this ever-changing landscape… This discussion covers: Why 2023 was the tipping point for AI applications. The difference between “narrow” and “generative” AI. How AI has taught itself various useful functions. The ways that AI can automate complex, text-based workflows. Dr. Lungren is the Chief Scientific Officer for Microsoft Health & Life Sciences. Currently, his work focuses on translating cutting-edge technology into innovative healthcare applications. As a physician and clinical machine learning researcher, he holds ongoing collaborative research and teaching roles as an adjunct professor at Stanford University. Dr. Lungren is the author of over 200 publications, with work spanning multi-modal data fusion, computer vision and NLP in healthcare, machine learning for public health screening, generative AI applications in medicine, and more. He also has experience advising early-stage startups and Fortune 500 companies on healthcare AI development and unique market strategies. His work has been featured by NPR, Vice News, and Scientific American, and he is a regular speaker at leading national and international conferences on AI in healthcare. Follow along with Dr. Lungren's work on X @mattlungrenMD! Episode also available on Apple Podcasts: http://apple.co/30PvU9C Keep up with Matthew Lungren socials here: Tiktok: https://www.tiktok.com/@dr.mattlungren  Instagram: https://www.instagram.com/matt_lungren/  YouTube: https://www.youtube.com/@mattlungrenmd 

This is the latest episode of the free DDW narrated podcast, titled "UK Spotlight: Innovation and discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Where is the drug discovery expertise happening in the UK?”, “From the top: Dr Martin Main, Medicines Discovery Catapult”, and “Meet the Researcher: Molly Stevens, Oxford University and Imperial”. In the first article, I highlight the research taking place and where this is happening in the UK, a long-established hub for drug discovery expertise worldwide.  In the second article, I spoke with Dr Martin Main, Chief Scientific Officer, Medicines Discovery Catapult, in the From the Top series.   In the third article, I spoke with Molly Stevens, John Black Professor at Oxford University and Research Director for Biomedical Materials at Imperial College London, as part of the Meet the Researcher series.

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC, twc.health/GRUBER, Promo Code GRUBER Saves 10% The new COVID variant has a nasty new symptom that has led the media to dub it as the “Razor Blade Throat” variant It feels a little coincidental that at a time that pharmaceutical profits are dropping and COVID vaccine boosters are at an all time low that this new scary sounding variant is out there  

Louise Jopling is the Chief Scientific and Innovation Officer at the Babraham Research Campus and Entrepreneur-in-Residence at the Babraham Institute. Sarah and Louise talk about Her career journey from immunology research to business leader and mentor Why hearing about the real-world impact of health innovations still gives her goosebumps The Babraham Research Campus ‘melting pot' which creates a unique environment for research commercialisation and collaboration Find out more Read the show notes and transcript on the podcast website Connect to Louise on LinkedIn Find out about the Babraham Research Campus and Babraham Institute   About Research Adjacent Fill out the research-adjacent careers quiz Sign up to the Research Adjacent newsletter Follow Research Adjacent on LinkedIn Instagram and BlueSky Email a comment, question or suggestion Leave Sarah a voice message

As our population ages, are we designing technology that truly meets their needs, or just what we think they need?In this episode of Straight Out of Health IT, Dr. Jennifer Boger, Chief Scientific Officer at ESGai Technologies, shares how her love for problem-solving and a personal connection to dementia led her into engineering and health technology. She underscores the flaws in current healthcare systems, particularly their focus on acute care over prevention and quality of life, and calls for a shift toward more holistic, person-centered approaches. Dr. Boger emphasizes that quality of life, though hard to quantify, should be a primary goal of healthcare. She also discusses the importance of designing inclusive technologies that are intuitive and respectful, noting that simplicity should not be mistaken for infantilization, especially when creating tools for older adults.Dr. Jennifer Boger explores the concept of ambient, zero-effort technologies, tools that are ubiquitous, accessible, and require minimal user effort. She and host Christopher Kunney agree that aging populations need technology that is easy to use without sacrificing dignity or privacy. They raise concerns about digital marginalization, warning that people who can't or choose not to use digital systems risk being excluded from essential services and even from AI-generated insights. Dr. Boger stresses the need for transparency in how data is collected and used, proposing clearer, more accessible summaries of privacy policies to empower users.Dr. Boger believes that while the concept of “considerate AI”, systems designed with ethical frameworks and human understanding in mind, holds promise, it is challenging to implement and will require time, patience, and brave, collaborative spaces. She envisions AI that supports rather than replaces human decision-making by prompting reflection and enhancing objectivity. Looking ahead, she sees natural language interfaces as a game-changer for independent living. For those entering the field, her advice is to connect directly with the people they're designing for, involving them early and often to ensure solutions are grounded in real-world needs and experiences.Tune in to learn how assistive technologies, ethical AI, and human-centered design can reshape aging, healthcare, and independent living! 

Experts warn AI and transhumanist biotech may render humans economically inessential, creating a “useless class” as machines outpace human intelligence. Surveillance of biological data by governments and corporations – mostly gathered through mass vaccination programs – could lead to total control, as your digital and bio data are decoded to manipulate decisions with an algorithm tailored to your specific beliefs and profile. Many fear a future “digital dictatorship” where surveillance strips away all privacy and enables streamlined control of citizens by corporations and governments. Dr. Peter McCullough examines the NB.1.8.1 variant's rapid rise and USDA's poultry vaccination plans, questioning COVID vaccine efficacy claims. Joe Allen discusses AI's cognitive impacts, misinformation about transhumanism, and the latest case of AI-driven false accusations. Dr. Peter McCullough is a renowned internist, cardiologist, and Chief Scientific Officer of The Wellness Company. He is co-author of the frequently-banned book The Courage to Face COVID-19. More at https://x.com/P_McCulloughMD⠀Joe Allen is the Transhumanism Editor for War Room and author of Dark Aeon: Transhumanism And The War Against Humanity. He's an expert in tech and religion. More at https://x.com/JOEBOTxyz 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • ACTIVE SKIN REPAIR - Repair skin faster with more of the molecule your body creates naturally! Hypochlorous (HOCl) is produced by white blood cells to support healing – and no sting. Get 20% off at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/skinrepair⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at ⁠⁠⁠⁠https://vshredmd.com/⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we have the second installment of our interview with Dr. Michael A. Schmidt, the founder, CEO, and Chief Scientific Officer of Sovaris Aerospace, a company focused on assessments and solutions applied to humans in space and extreme environments on Earth. In today's interview, we talk to Michael about NASA's plans to send humans to Mars and build permanent colonies on the Moon and Mars. We also talk to Michael about his recent book, “Building a Space-Faring Civilization,” which addresses the challenges of civilian spaceflight and the construction of space settlements. In part one of our interview, Episode 182, we talked with Michael about his pioneering work in the field of precision medicine and how he has used it to improve the cognitive and physical performance of astronauts as well as NBA, NFL players and Special Operations forces. In addition to his work with Sovaris, Michael also is a professor of aerospace medicine at the University of Central Florida College of Medicine, one of the few programs in the U.S. that offers a medical residency in aerospace medicine. Show notes: [00:03:00] Dawn picks up our interview from where we left off in part one, discussing the Human Research Program for Civilian Spaceflight. She goes on to mention that Chris Mason at Cornell University has a biobank of 1,500 samples across 22 astronauts and seven missions, and that these samples will lead to deeper insights on the effects of spaceflight on humans. Dawn switches gears to ask Michael about the cognitive and physical challenges of spaceflight over long duration missions. [00:13:03] Following up on the cognitive challenges of long duration spaceflight, Ken mentions that the hippocampus, the primary memory center of the brain, has a relatively low radiation threshold compared to other tissues in the brain. Ken asks Michael to touch on the vulnerability of specialized brain tissues to radiation, particularly in the context of a long duration spaceflight to Mars. [00:21:53] Ken mentions that it is understood that the APOE4/4 genotype is associated with impaired cognitive performance under certain circumstances and an elevated risk of dementia. While it is currently unknown whether APOE4/4 has any correlation of increased risk associated with cognitive impact resultant from environmental exposure due to spaceflight, Ken highlights the concern with sending APOE4/4-positive astronauts on long duration spaceflights without knowing the risks. [00:29:26] Ken notes the worsened cognitive impacts resultant from medical radiation, and while therapeutic radiation is different than radiation experienced by astronauts, these results give some indication of the effects astronauts might experience. [00:33:27] Dawn mentions that we recently had planetary scientist and director of NASA's Haughton-Mars project, Pascal Lee, on the podcast, who explained his view that since there are so many engineering and biological challenges with going to Mars, we should take a more measured approach to a Mars mission, perhaps even beginning with a roundtrip to Mars rather than landing on our first visit. Dawn asks Michael what his thoughts are on this approach. [00:37:29] Ken shifts the discussion to the subject of one of Mars' moons, Phobos, and its potential role in a Mars mission. [00:40:30] Dawn pivots to talk about Michael's Book “Building a Space-Faring Civilization: Advancing the Renaissance of Science, Medicine and Human Performance in Civilian Spaceflight.” Dawn asks Michael to talk about the chapter concerning the question of space radiation from the standpoint of precision medicine. [00:55:12] Dawn asks Michael to talk about the lack of appreciation people have for the fact that a Mars mission would be the most dangerous thing we've ever done. [00:59:06] Ken mentions that Michael has worked with a lot of organizations, including Space X, which has a program, the Space X Mars Colonization Program,

What every healthcare leader should know is at the heart of this episode featuring Dr. Todd Brinton, Chief Scientific Officer at Edwards Lifesciences and a leading figure in medtech innovation. Dr. Brinton's journey began in a sixth-grade classroom, where a fascination with the heart sparked a lifelong passion for both medicine and technology. That early curiosity led him to pursue engineering, medicine, and eventually leadership in heart health. Before becoming a recognized leader, Dr. Brinton faced the same questions many young professionals do—wondering if he belonged, and whether he could move from engineering into medicine. Throughout his career, mentors played a crucial role in helping him find his potential, and setbacks became opportunities for growth. These experiences shaped his approach to leadership, resilience, and innovation in healthcare. Dr. Brinton discusses lessons learned from building teams, founding companies like Shockwave Medical and BioParadox, and making difficult choices as both a physician and entrepreneur. He shares why honesty and kindness matter in leadership, how to create meaningful mentor relationships, and what it really takes to move ideas from the clinic to the corporate world. The conversation covers why embracing mistakes is essential for progress, why people—not just technology—will define the future of health innovation, and advice for those building their own path in healthcare. Whether you're leading a startup, managing a hospital team, or just starting your career, Dr. Brinton's story offers practical insight for every stage. Hear directly from Dr. Todd Brinton as he joins Christine Winoto for a candid discussion about career pivots, mentorship, and the realities of healthcare leadership, brought to you by the UCSF Rosenman Institute. For more on healthcare innovation, check out What 2 Billion Data Points Can Tell Us: James Mault on Smarter Care. Do you have thoughts on this episode or ideas for future guests? We'd love to hear from you. Email us at hello@rosenmaninstitute.org.

Dr. Ebru Karpuzoglu is an immunologist and molecular medicine expert, and the Chief Scientific Officer and CEO of Aveseena. Dr. Karpuzoglu discusses "inflammaging," a condition where inflammation and premature aging occur simultaneously, triggered by factors such as stress, diet, and harsh skincare practices. Dr. Karpuzoglu highlights the skin's role as the first line of immune defense, protected by its microbiome and immune system. Disclosure: Dr Ebru is an executive for a for profit skin care product and service line. Learn more about Dr. Ebru and her company Aveseena here: https://www.aveseena.com/about-us/

In this episode, we sit down with Dr. Mark Esser, the inaugural Chief Scientific Officer of UVA's new Paul and Diane Manning Institute of Biotechnology. Dr. Esser, a renowned expert in immunology and vaccine development, shares his journey from AstraZeneca to leading this ambitious institute. With a vision to revolutionize healthcare and accelerate the development of life-saving treatments, Mark discusses fostering innovation, attracting biotech companies to Virginia, and the future of personalized medicine.

In this episode of The Pet Food Science Podcast Show, Lars Reimann and Kari Nichols from Eurofins Scientific explain the science behind analytical testing and regulatory compliance in the pet food world. They talk through the new label modernization rules, why ingredient consistency matters, and what makes testing fiber and shelf life so tricky. You'll also hear how lab methods are adapting to keep up with industry demands. Tune in now on your favorite podcast platform!"Crude fiber remains a necessary component in determining calories from carbohydrates, despite no longer being listed on pet food product labels." - Kari NicholsMeet the guests: Lars Reimann, Chief Scientific Officer at Eurofins Scientific, brings over 35 years of experience helping pet food clients navigate analytical, nutritional, and regulatory testing.Kari Nichols, Vertical Business Development Manager for Pet & Animal Nutrition, has 11 years of experience in lab services, specializing in food safety and label compliance.Dr. James Templeman & Lindsay Meyers: Raw Pet Food | Ep. 96Liked this one? Don't stop now — Here's what we think you'll love!What will you learn:(00:00) Highlight(01:01) Introduction(03:37) Labeling regulation changes(06:00) Dietary vs crude fiber(12:54) Fiber testing methods(28:49) Analytical methods matter(36:57) Shelf life evaluations(42:47) Final QuestionsThe Pet Food Science Podcast Show is trusted and supported by innovative companies like:* Trouw Nutrition* Kemin- EW Nutrition- Wilbur-Ellis Nutrition- ICC- Biorigin- Scoular

Jackie von Salm, a chemist and Chief Scientific Officer at Psilera, shares her father Terry's journey with FTD. We loved how Jackie was so raw + honest about family dynamics, becoming Terry's POA in her 20s, and how she learned how to be direct + honest in how she felt and what she needed while caregiving. You can learn more about what she's up to at Psilera here. You can also hear us chat all about their Research Summit this year on Patreon - along with an extended version of this episode.Patreon⁠⁠⁠⁠⁠ - join us ⁠⁠⁠⁠⁠www.patreon.com/remembermecommunity⁠⁠⁠⁠⁠ - you get exclusive content and it's a great way to support the show!----------Special thank you to today's sponsor ⁠⁠AVIADOBIO⁠⁠.If you're curious about anything RM, we'd love to connect with you on ⁠⁠⁠⁠⁠⁠⁠⁠Instagram, and visit ⁠⁠⁠⁠⁠our website at⁠⁠⁠⁠⁠⁠⁠⁠ www.remembermeftd.com⁠⁠⁠⁠⁠⁠⁠⁠, all the latest updates! ------Remember Me Podcast + Community is here to offer hope + human connection for families, caregivers, and individuals impacted by Frontotemporal Dementia (FTD). Always, always accept the good.

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Download the transcript here

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Listen to the podcast here

On this week's Tech Nation, Moira speaks with Warren Berger, author of  “A More Beautiful Question … The Power of Inquiry to Spark Breakthrough Ideas”, now in its tenth anniversary re-release and update. Then, Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics, tells us about how a treatment can turn into a vaccine and potentially provide long-lasting protection against cancer.

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors. Citylabs 4.0, now open in the heart of Manchester's Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organisations into close, purposeful proximity, providing a structural foundation for collaboration at scale. In this special live recording of the pharmaphorum podcast, developed in association with Bruntwood SciTech, Bruntwood SciTech's CSO Dr Kath Mackay, Manchester University NHS Foundation Trust T's Dr Katherine Boylan, and Dr Gillian Dalgliesh from QIAGEN join Deep Dive editor Eloise McLennan onstage at the opening of Citylabs 4.0 to discuss innovation in life sciences and the role of Greater Manchester in accelerating research, industry collaboration, and real-world evidence generation. Join us as we examine how this deliberate integration of healthcare stakeholders in Manchester is establishing new standards for collaboration and advancing patient outcomes through structured knowledge exchange. About the interviewees Dr Kath Mackay Kath Mackay is Chief Scientific Officer of Bruntwood SciTech - a JV between leading property developer Bruntwood, Legal & General, and Greater Manchester Pension Fund - the UK's leading creator and developer of innovation districts driving growth of the UK science and technology sector.  She has a keen interest in growing businesses and infrastructure within the sector, ensuring the UK is the best place to establish and scale a science and tech organisation.   Dr Mackay joined Bruntwood SciTech from the executive board of Innovate UK where she led the team responsible for growing businesses working in the biomedical, health, agriculture, and food sectors, creating and delivering a £800m portfolio of infrastructure, Catapults, grant and loan investments. She is also non-executive director of the Northern Health Science Alliance, the North of England's health partnership, and an elected fellow of the Royal Society of Biology. Dr Katherine Boylan Katherine is Director of Innovation at Manchester University NHS Foundation Trust (MFT), a position she has held since April 2020. This role involves overseeing innovation activities within MFT, as part of the wider Research and Innovation function. Innovation at MFT supports the whole pipeline from ideation, through to evidence generation, and ultimate implementation. She has been a member of the NICE Medical Technologies Advisory Committee since September 2020. Prior to this position, Dr Boylan worked in the University of Manchester for a number of years, most recently as Operations Director for the MRC funded Molecular Pathology Node, and the Trust-funded Diagnostics and Technology Accelerator. Dr Gillian L Dalgliesh, PhD Global Technical lead, Precision Diagnostics Gillian Dalgliesh has worked for QIAGEN for nine years and is based at their Manchester site, which is the global centre of excellence for molecular diagnostic development. QIAGEN partner with many drug companies to develop companion diagnostic (CDx) tests that enable clinical trials and subsequently launches of novel precision medicines. In recent years they have seen a real move beyond oncology into other disease areas such as immune, neurological and metabolic disorders. Dr Dalgliesh's role as global technical lead allows her to leverage her oncology precision medicine experience across the portfolio to bring precision diagnostic products to more patients. She has built her experience in precision medicine/oncology through not only her QIAGEN role but also through seven years working in precision medicine in AstraZeneca and prior to that working as part of the cancer genome project at the Sanger institute. Dr Dalgliesh is also an honorary senior lecturer at University of Manchester where she coordinates and delivers lectures for a QIAGEN sponsored BSc final year elective module ‘The Role of Diagnostics in Medicine'. This is part of a wider outreach role with the University and our NHS hospital. Through these roles she is keen to impact the local UK science community. About Bruntwood SciTech Bruntwood SciTech is the UK's largest dedicated property platform serving the growth of the nation's knowledge economy to become a global science and technology superpower. It is also the leading developer of city-wide innovation ecosystems and specialist environments, helping companies - particularly those in the science and technology sectors - to form, scale and grow A joint venture between Bruntwood, Legal & General and the Greater Manchester Pension Fund (GMPF), Bruntwood SciTech provides high quality office and laboratory space and tailored business support, offering unrivalled access to finance, talent and markets, an extensive clinical, academic and public partner network and a sector-specialist community of more than 1100 companies. Bruntwood SciTech is experienced in creating and developing strategic partnerships with UK regional cities, universities and NHS Trusts to drive economic growth. Its unique structure and funding vehicle more easily deploys long-term patient capital in innovation infrastructure, ensuring local economic benefit and growth. Valued at £1.5bn, Bruntwood SciTech has a portfolio of 5.2m sq ft across 11 campus locations and 31 city centre innovation hubs in Manchester, Cheshire, Birmingham, Leeds, Liverpool, Cambridge and London. It has plans to create a £5bn portfolio by 2033 and has a 2.3m sq ft secured development pipeline. Its campus locations include Alderley Park in Cheshire; West Village in Leeds; Innovation Birmingham; Birmingham Health Innovation Campus in partnership with the University of Birmingham; Melbourn Science Park in Cambridgeshire; Liverpool Science Park as a shareholder in Sciontec Liverpool; White City Deep Tech Campus in partnership with Imperial College London; and a cluster in the heart of Manchester's Oxford Road Corridor knowledge quarter - Manchester Science Park, Citylabs in partnership with Manchester University NHS Foundation Trust (MFT), Circle Square - a joint venture with Vita Group; and the £1.7bn JV partnership with The University of Manchester - Sister, formerly known as IDManchester. Its city centre innovation hubs include Bloc, Bond, 111 Piccadilly, Pall Mall and Manchester One in Manchester; Platform in Leeds; Cornerblock and Centre City in Birmingham; and The Plaza in Liverpool. Website / Twitter / LinkedIn / Instagram

Are wellness retreats just luxury getaways, or can they transform your health? In this episode of the Habits and Hustle podcast, I speak with Dr. Vishal Patel, who explains how most wellness gadgets might be causing more stress than health benefits.  We explore the science behind Sensei's approach, including how thermal imaging can detect muscular imbalances before they cause pain, and why most saunas aren't hot enough to deliver benefits. Dr. Patel debunks popular wellness myths, shares why foot strength is the foundation of longevity, and explains why tracking obsession can be counterproductive.  Dr. Vishal Patel is the Chief Scientific Officer at Sensei, a wellness retreat company co-founded by Larry Ellison and Dr. David Agus. With a background as a physician with a PhD in genetics, Dr. Patel combines Western medicine with Eastern practices like Ayurveda to create evidence-based wellness approaches that focus on personalization rather than rigid rules. What We Discuss:  03:02 Personalized Wellness Programs 05:51 The Science of Eating and Nourishment 08:56 Understanding Body Mechanics for Longevity 12:03 Vishal Patel's Background and Expertise 14:54 Debunking Wellness Myths and Misinformation 20:13 The Science Behind Wellness Trends 25:14 Exploring Infrared Saunas and Their Efficacy 30:00 The Role of Data in Health Tracking 35:29 Understanding Plasmapheresis and Its Implications …and more! Thank you to our sponsors: Therasage: Head over to therasage.com and use code Be Bold for 15% off  TruNiagen: Head over to truniagen.com and use code HUSTLE20 to get $20 off any purchase over $100. Magic Mind: Head over to www.magicmind.com/jen and use code Jen at checkout. Air Doctor: Go to airdoctorpro.com and use promo code HUSTLE for up to $300 off and a 3-year warranty on air purifiers.  Bio.me: Link to daily prebiotic fiber here, code Jennifer20 for 20% off.  David: Buy 4, get the 5th free at davidprotein.com/habitsandhustle.   Find more from Jen:  Website: https://www.jennifercohen.com/ Instagram: @therealjencohen   Books: https://www.jennifercohen.com/books Speaking: https://www.jennifercohen.com/speaking-engagement Find more from Dr. Vishal Patel: Website: https://sensei.com/  LinkedIn: https://www.linkedin.com/in/vishal-n-patel-md-phd/ 

In this episode of the "Metabolic Freedom Podcast," host Ben Azadi sits down with Alessandra Zonari, who is the co-founder and Chief Scientific Officer of OneSkin. They explore the fascinating science behind skin aging, particularly focusing on senescent cells, often referred to as "zombie" cells. These cells tend to build up as we age and play a significant role in skin deterioration. Alessandra shares insights into OneSkin's groundbreaking approach, which involves using the OS1 peptide to reduce these cells and promote healthier skin. They also discuss why it's crucial to have scientific evidence backing skincare products, how lifestyle and environmental factors can affect skin health, and the advantages of using non-toxic ingredients. The episode highlights the importance of making informed skincare choices for overall well-being.

Today we have Dr. Michael A. Schmidt, the founder, CEO, and Chief Scientific Officer of Sovaris Aerospace, a company focused on assessments and solutions applied to humans in space and extreme environments on Earth.  Michael is also a professor of aerospace medicine at the University of Central Florida College of Medicine, one of the few programs in the U.S. that offers a medical residency in aerospace medicine. Michael is known for his work pioneering the field of precision medicine. He uses molecular analytics, coupled with physiologic and behavioral assessments, to facilitate human performance and resilience on Earth as well as in the extreme environment of space. His work covers a spectrum from NASA, the NFL, the NBA, U.S. Olympic teams, Nike, SpaceX, Axiom Space, NASCAR, Special Operations, the Naval Submarine Medical Research Lab, the Mayo Clinic, and others. We had a long and fascinating conversation with Michael and decided to break the interview into two parts. This episode focuses on Michael's background and the cognitive and physical challenges astronauts experience in spaceflight. We also dive into the many ways that precision medicine is facilitating human performance and resilience here on Earth. In part two of our conversation, Michael talks about his work with NASA and SpaceX on the challenges of civilian spaceflight and the future of Mars exploration, including the construction of permanent colonies on the Moon and Mars. You won't want to miss that conversation. Show notes: [00:03:59] Dawn opens our interview mentioning that Michael grew up in Minnesota in a small farming community, asking if it's true that he sometimes had to do chores in 20- to 30-degree weather. [00:06:50] Dawn asks if it is true that Michael fell in love with science at a young age, even building telescopes at the age of 11. [00:08:00] Dawn asks Michael what it was that led him to become so fascinated with space specifically. [00:08:58] Dawn asks if Michael ever thought about becoming an astronaut. [00:10:09] Ken asks if it is true that Michael was a big reader as a child. [00:11:21] Dawn asks Michael to talk about his childhood athletic interests. [00:11:55] Dawn asks how it was that a high school quarterback from a small town in Minnesota ended up at university in the United Kingdom. [00:13:38] Ken asks Michael what years he worked at NASA Ames Research Center. [00:14:51] Ken mentions that when Michael was at NASA Ames, he did work collecting molecular and physiologic assessments of humans using NASA's 20-G centrifuge. Ken asks Michael to talk about the centrifuge and how he used it in his studies of hypergravity. [00:17:49] Ken comments on the fact that pieces of equipment like NASA's 20-G centrifuge are a precious scientific resource, and when they cease functioning, unfortunately, they are unlikely to be replaced. [00:19:40] Ken and Michael discuss the fact that microgravity, despite being one of the most pressing effects on astronaut health, is the one of the least addressed problems in human spaceflight. [00:21:48] Ken explains that Michael is the founder, CEO and Chief Scientific Officer of a company called Sovaris Aerospace, which is focused on assessments and solutions applied to humans in space and extreme environments on Earth. Ken asks Michael where the idea came from to found this company. [00:24:35] Dawn explains that since the human genome was first sequenced, there has been an acceleration of genome-based technologies that have made it possible to consider a person's genetic makeup, both in healthcare and optimizing performance. Dawn asks Michael to talk about the work he does applying genomics to human spaceflight. [00:28:52] Dawn asks about Michael's direction of the molecular profiling and precision medicine efforts for the Golden State Warriors during their record-breaking 73-9 season [00:32:57] Dawn mentions that Michael published a review in the journal Meta...

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. Visit twc.health/GRUBER and use Promo Code: GRUBER Secretary Kennedy announced the removal of the COVID vaccine from the CDC's recommended schedule, for 'healthy children and healthy pregnant women."

All Home Care Matters and our host, Lance A. Slatton were honored to welcome the team behind the Dementia Care Family Support Program.   About Denise M. Brown:   Denise began supporting family caregivers in 1990, launching one of the first online caregiving communities in 1996. She trains Caregiving Consultants, Facilitators, Guides and Navigators. She cared for her father for almost 20 years and for her mother for 8 years.   She's written 16 books for current and former family caregivers.    About Dr. Laura Gitlin:   Dr. Laura Gitlin is the Co-founder and Chief Scientific Officer at Plans4Care. She is an intervention scientist with over 40 years of experience in dementia care and research. Dr. Gitlin currently serves as a multiple Principal Investigator on several NIH-funded grants, where she leads the development and testing of innovative interventions to support people living with dementia and their caregivers.   About Eric Jutkowitz, PhD:   Eric Jutkowitz, PhD is the Co-founder and CEO of Plans4Care. He is health services focused on improving the nation's long-term care system. He co-founded Plans4Care to bring evidence-based dementia care out of the university and into the hands of all family caregivers.   About the Dementia Care Family Support Program:   Our Certified Caregiving Consultants partnered with Plans4Care, a technology start-up to offer 5 coaching sessions to dementia family caregivers in order to resolve 3 care challenges.   We'll share what we learned about using technology during coaching sessions, the common care challenges we addressed and the insights we gained from tracking our coaching sessions. We also will talk about what we learned about how to best support dementia family caregivers to help ease their stress and worries.

What does it take to challenge the deadliest brain tumors with sound waves? How do you scale a medtech startup into a multinational clinical company? And what advice can a top neuro-oncology innovator offer to those hoping to follow a similar path? Welcome to Neurocareers: Doing the Impossible! — The podcast where we explore the extraordinary journeys of those advancing the future of neuroscience and neurotechnology. I'm your host, Dr. Milena Korostenskaja. Today we're speaking with Dr. Michael Canney, the Chief Scientific Officer at Carthera, a clinical-stage medtech company revolutionizing brain therapy through therapeutic ultrasound. With over 15 years of experience in MedTech innovation, Dr. Canney specializes in glioblastoma, neurodegenerative diseases, and therapeutic ultrasound drug delivery. He's currently leading the SONOBIRD Phase 3 clinical trial across 40 sites in the U.S. and Europe, pushing the boundaries of what's possible in treating recurrent glioblastoma. Michael's career spans everything from FDA regulatory strategy to high-impact academic collaborations. He's co-authored over 50 peer-reviewed papers in top-tier journals and 14 patent families. But what truly drives him is improving patient outcomes and bringing hope to some of the most challenging areas in brain health. Whether you're curious about clinical trials, neuro-oncology innovations, or carving out your own career in medtech, this conversation is packed with insight and inspiration. Let's dive in! Chapters: 00:00:01 - Revolutionizing Brain Therapy with Ultrasound, Introducing Dr. Michael Canney 00:04:49 - Advancements in Ultrasound for Drug Delivery 00:10:15 - Innovative Ultrasound for Drug Delivery 00:13:49 - Innovative Ultrasound Approach for Tumor Treatment 00:16:02 - Understanding Blood-Brain Barrier Disruption 00:19:28 - Device Overview and Design Features 00:21:32 - Ultrasound Technology for Tumor Treatment 00:24:15 - Device Implantation in Cancer Treatment 00:28:34 - Challenges in Glioblastoma Treatment Trials 00:31:46 - Dr. Michael Canney's Journey into Ultrasound Research 00:36:15 - Starting a Postdoc Journey 00:39:20 - Career Development in Neuroscience 00:43:31 - Building a Startup Team 00:47:38 - Hiring for Clinical Application Specialists 00:52:16 - Growth of Careers in Neurotechnology 00:54:26 - Using AI in Clinical Trials 00:57:13 - Challenges in Medical Device Approval 00:59:41 - Overcoming Challenges in Medical Innovations 01:02:20 - Clinical Trials and Company Information About the Podcast Guest: Michael Canney, Ph.D., is Chief Scientific Officer at Carthera, a clinical-stage medtech company advancing brain therapy through innovative ultrasound-based devices. A co-author of more than 50 peer-reviewed articles, he specializes in neuro-oncology, glioblastoma and neurodegenerative diseases. At Carthera, he is responsible for leading scientific collaborations with academic institutions, organizing U.S. clinical trials and more. Connect with Dr. Canney on LinkedIn: https://www.linkedin.com/in/michael-canney-ph-d-42457b5/ Learn more about Carthera: https://carthera.eu/ Get familiar with the Sonobird clinical trial: https://sonobird.eu/ About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in neurotech and Brain-Computer Interfaces, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume, and cover letter development Neurotech / neuroscience job interview preparation and practice Networking strategies to connect with professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news  

On this episode of The Kara Goldin Show, we're joined by Catharine Arnston, Founder, CEO, and Chief Scientific Officer of ENERGYbits®—the pioneering brand bringing the power of algae to the forefront of wellness, energy, and longevity. After a deeply personal experience with a family health crisis, Catharine made it her mission to educate the world about the incredible health benefits of spirulina and chlorella—long before they became trendy.In our conversation, Catharine shares the early days of discovering algae's healing potential, what inspired her to build ENERGYbits, and why she believes algae is the most powerful superfood on the planet. We dive into the science behind spirulina and chlorella, the major obstacles she faced educating consumers, and how she's grown ENERGYbits into a trusted brand used by athletes, biohackers, and wellness seekers worldwide. Catharine also opens up about the resilience it takes to build a movement from scratch, the leadership lessons she's learned, and the habits that keep her going strong.Whether you're a health-focused founder, a nutrition enthusiast, or someone curious about building brands with real mission and impact, this episode is packed with insights you won't want to miss. Now on The Kara Goldin Show. Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks. To learn more about Catharine Arnston and ENERGYbits®:https://www.instagram.com/energybitshttps://www.linkedin.com/in/catharinearnstonhttps://www.youtube.com/energybitshttps://www.facebook.com/ENERGYbitshttps://www.twitter.com/energybitshttps://www.instagram.com/catharinearnston/https://www.energybits.com Sponsored By:Range Rover Sport - The Range Rover Sport is your perfect ride. Visit RangeRover.com/us/Sport and check it out. Check out our website to view this episode's show notes: https://karagoldin.com/podcast/692

Peter A McCullough, MD, MPH, Chief Scientific Officer, TWC. twc.health/GRUBER. Promo Code GRUBER Saves 10% What came out at the WED May 21 Senate Hearing on Vaccine Myocarditis?

Blockchain Ireland's annual conference serving the blockchain, crypto and Web3 communities, Blockchain Ireland Summit 2025 kicks off this Friday. One of the speakers at the two day conference is Richard Blythman the Co-founder and Chief Scientific Officer of Naptha.AI, a startup building open, decentralised infrastructure for the next generation of AI. Richard's background is in machine learning, engineering, and academic research, and his work focuses on enabling developers to build intelligent agents that can work together, without relying on centralised platforms or Big Tech infrastructure. Ronan recently caught up with Richard. Richard talks about his background, the internet of agents, what naptha does, AI privacy, eu regulation and more.More about Richard Blythman:He previously co-founded Algovera, one of the earliest players in the decentralised AI sector, and holds a PhD in Engineering from Trinity College Dublin. His experience spans from building generative models and digital avatars in Big Tech, to leading research on fluid dynamics, multi-agent coordination, and privacy-preserving AI systems.At Naptha, Richard is exploring how decentralised agent networks could reshape everything from software development to data ownership, and why open standards like MCP are key to unlocking that future.

Today, we have another episode in our series of thoughtfully curated companies. This episode is sponsored by OneSkin, a company founded and led by an all-female team of PhD-level scientists. OneSkin is redefining how we think about aging, starting with the skin, our largest organ. I am delighted to introduce Dr. Alessandra Zonari as our guest today. Dr. Zonari is far from your typical scientist. She is a true visionary with a passion for longevity, skin regeneration, and an occasional karaoke jam. With degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Dr. Zonari brings a wealth of knowledge and a fresh perspective to our conversation today. Join us to learn more about OneSkin and how their products can reverse the effects of biological aging, helping your skin become stronger and more resilient as you age. IN THIS EPISODE YOU WILL LEARN: Dr. Zonari shares her mission to understand how skin can age healthier and stronger and reduce the risk of inflammation and diseases.  How the female-led research team at OneSkin brings a unique perspective to skincare How the OneSkin peptide can reverse 2.5 years of biological aging in just five days The unique way in which they test their products and measure biological aging at OneSkin  How estradiol loss during menopause exacerbates the accumulation of senescent cells and causes inflammation Some common misconceptions about skincare for women in perimenopause and menopause How lifestyle choices influence the aging process of the skin  Why we must protect the skin from environmental stressors to slow the aging process  How your skin cells can get reprogrammed to return to a youthful state How OneSkin developed a hair care line to address hair loss and thinning The importance of self-love and nourishing your body  ABOUT OneSkin:  Founded and led by an all-woman team of PhD-level scientists, OneSkin is transforming the way we think about aging, starting with the body's largest organ, the skin. Our proprietary OS-01 (oh ess one) peptide is the first ingredient to reverse the biological age of skin by targeting cellular senescence, a key driver of aging. By targeting cellular senescence, the OS-01 peptide switches off the damaged cells that contribute to lines, wrinkles, and sagging skin. The result? Skin that looks and behaves younger. Our products are designed for young and mature skin, because it is never too early or too late to invest in your skin health! We create next-level skin care. BIO: Alessandra Zonari, PhD, OneSkin Co-Founder & CSO Alessandra is not your typical scientist. She is a visionary with a passion for longevity, skin regeneration, and the occasional karaoke jam. Growing up in a close-knit family in Brazil, Alessandra saw her grandparents struggle with age-related diseases, and she soon became fascinated by the possibility of using stem cells to redefine the aging process. After earning degrees in biology and stem cell biology and a doctorate in skin regeneration and tissue engineering, Alessandra joined OneSkin in 2017 as a founding member and Chief Scientific Officer. Her contributions include 20+ papers, three patents, and the development of their proprietary OS-01 peptide. Connect with Cynthia Thurlow   Follow on X Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Alessandra Zonari On the ONESKIN website ONESKIN on Instagram Interested in trying OneSkin for yourself? Visit oneskin.co/CYNTHIA and use code CYNTHIA for 15% off your first purchase!

Prime Minister Mark Carney unveiled his new cabinet this week, but he won't be unveiling a budget this year — a move that drew plenty of criticism from his opponents. Newly appointed Industry Minister Melanie Joly joins The House to discuss the decision and weighs in on the new government's other economic priorities. Then, two Hill watchers offer their takes on whether Carney's cabinet picks deliver on his promise for change.Plus, weeks after the election, dramatic recounts are still underway in a handful of ridings, and those results could shake up the House of Commons even further. An elections expert explains what's happening and whether the flip-flopping risks undermining confidence in elections.Finally, measles cases are rising in some parts of the country and provinces are under fire for not doing enough to keep the public better informed. Two doctors talk to Catherine Cullen about what can happen when politics and a deadly disease collide.This episode features the voices of:Melanie Joly, Minister of IndustryShannon Proudfoot, writer for The Globe and Mail's Ottawa bureauPaul Wells, author and podcasterHolly Ann Garnett, associate professor of the Royal Military College of CanadaDr. James Talbot, former Chief Medical Officer of Health for AlbertaDr. Kumanan Wilson, Chief Scientific Officer of Bruyère Health Research Institute

Episode 051 | Greg Maguire, PhD is the Co-Founder of the SRM Living Foundry at UCSD in San Diego and the Co-Founder & Chief Scientific Officer of NeoGenesis, a wonderful company I talk with my patients about all the time. If you haven't yet listed to episode 047 featuring Christine Preston, that one pairs delightfully with my conversation with Dr. Maguire.Awarded a prestigious Fulbright-Fogarty Fellowship from the National Institutes of Health, Dr. Maguire managed his NIH funded laboratory at UCSD studying tissue degeneration and regeneration, and the role of stem cell released molecules (SRM) through paracrine and autocrine actions to maintain, repair, and regenerate human tissues. His NIH funded studies of systems biology and reverse engineering at UC Berkeley and stem cell biology at UC San Diego led to the development of adult stem cell-based S2RM® technology for the development of therapeutics and medical procedures.Dr. Maguire pursued his graduate training at the University of California, Berkeley, University of Houston, University of Texas, The Marine Biological Labs, Woods Hole, MA, and Cold Spring Harbor Laboratory, NY. He is a former professor of neuroscience and ophthalmology at the University of California, San Diego School of Medicine, a visiting associate professor of physiology at Keio University School of Medicine in Tokyo, Japan, visiting assistant professor of molecular neurobiology at the University of Washington, and a visiting scientist at Massachusetts General Hospital (MGH), at Harvard University.Dr. Maguire has over 100 publications and is currently working on his book entitled, “Spontaneous Stem Cell Healing”.The Above & Beyond Dermatology podcast is grateful to NeoGenesis for the great work they do and for their generous support of this episode. If you're a skin care professional and would like to learn more about helping your customers with NeoGenesis, click here to learn more. If you'd like to learn directly from the NeoGenesis team, text me at 715-391-9774 and I'll be happy to make a warm introduction.Connect with and learn from Greg Maguire & NeoGenesisLearn & Shop NeoGenesisDr. Maguire's Skin Care BlogNeoGenesis Wholesale Partnership for Medical ProfessionalsMore from Dr. Lewellis and Above & Beyond DermatologyNeed a dermatologist? Fill out this short interest form, text or call me at 715-391-9774, or email me at drlewellis@aboveandbeyondderm.com if you'd like to have a no obligation discovery call. I offer in-office visits, house calls, and virtual care in Wisconsin and virtual care in Illinois, Nebraska, and Colorado.Have an idea for a guest or want to be on the show yourself? Send me a text or email, and we'll see if it's a good fit.

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical research?” and “What spatial biology can tell us about disease and drug discovery”. In the first article, DDW Editor Reece Armstrong speaks to Dr Darrell Green, Lecturer in RNA Biology, Biomedical Research Centre, Norwich Medical School University of East Anglia, about his work using next generation sequencing (NGS) and the areas the technology is impacting within drug discovery and development. In the second article, Diana Spencer catches up with Lorna Ewart, PhD, Chief Scientific Officer of Emulate, about the rise of organ-on-a-chip technology. In the third article, DDW Editor Reece Armstrong speaks to Benedikt Nilges, Head of Technology and Data Analytics at OMAPiX about spatial biology's use in drug discovery and bettering our understanding of disease.

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Listen to the podcast here

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Download the transcript here

CareQuest Institute for Oral Health is a national nonprofit dedicated to creating an oral health care system that is accessible, equitable, and integrated. Learn more about how their advocacy, philanthropy, research, and education are creating a better oral health system at carequest.org/turnonthelights What happens when the power of large language models meets the complexity of modern medicine? In this episode, Eric Horvitz, Chief Scientific Officer of Microsoft, discusses the transformative impact of artificial intelligence in health care, particularly the shift from rule-based systems to data-driven models like GPT-4. He highlights how AI can reduce physician burnout by handling administrative tasks and supporting clinical decision-making. Eric emphasizes the importance of AI collaborating with, rather than replacing, health care professionals to improve diagnostic accuracy and patient safety. He also explores future possibilities, including personalized health companions, intelligent patient portals, and AI-powered tumor board simulations. Overall, he underscores both the exciting potential and the responsibility involved in integrating AI safely and meaningfully into health care. Tune in for a thought-provoking conversation on how AI is transforming health care, from easing clinician burden to reimagining patient care and medical decision-making! Learn more about your ad choices. Visit megaphone.fm/adchoices

Peter A McCullough, MD, MPH, Chief Scientific Officer, The Wellness Company  twc.health/GRUBER | Promo Code GRUBER Saves 10% Spaces Event TONIGHT (5/7) on The Steve Gruber Show X account  RFK Jr announces a new “Take Control of Your Health” campaign "We Need a Great Reset in Health" The need to stockpile prescription medication

We catch up on the tri news and racing from the weekend and give our thoughts on the announcement that the IM World Champs is moving back to Kona. Alison Heather is a former academic professor whose research has focused for over 24 years' on the physiology of steroid hormones and their role in health and disease. She has international recognition for her development of bioassays for the detection of steroid hormones. Alison acts as an advisor to many High Performance Sport Teams including those focusing on female athlete health, triathlon, cycling, running and sports supplements and is currently the Chief Scientific Officer for plasmaide In this conversation, we discuss the supplement Plasmaide, its origins and its benefits for athletes. Dr Heather explains the science behind nitric oxide production, the ingredients in Plasmaide and how it compares to other supplements like beetroot juice. The discussion covers both acute and chronic benefits of Plasmaide, its adaptogenic properties and its influence on carbohydrate metabolism. Dr. Heather also provides practical advice for using Plasmaide safely and effectively, emphasizing the importance of consulting with a healthcare professional before starting any new supplement regimen. (0:00:00) – A weekend of bike crashes (0:09:22) – T100 goes to the Gold Coast in 2026 (0:15:51) – The racing from IM703 Venice and IRONMAN Australia  (0:24:16) – IRONMAN World Champs moves back to Kona (0:40:05) – Dr Alison Heather intro (0:41:38) – Dr Alison Heather LINKS: Dr Alison Heather at https://www.insitugen.com/ Plasmaide at https://plasmaide.com.au/ Live Feisty podcast at https://livefeisty.com/podcasts/feistytriathlon/ironman-goes-backwards-special-world-champs-episode/ Pro Tri News podcast at https://protrinews.buzzsprout.com/1736374/episodes/17067560-episode-217-kona-is-back-with-ironman-ceo-scott-derue 2025 Oceania Triathlon Super-Sprint Championships Runaway Bay at  https://triathlon.org/events/2025-oceania-triathlon-super-sprint-championships-

This week on The Genetics Podcast, Patrick is joined by Madhuri Hegde, SVP and Chief Scientific Officer of Revvity. They discuss Revvity's advances in ultra-rapid clinical-grade sequencing, opportunities, challenges, and global inequities in newborn screening, and the dilemma of resequencing versus long-term data storage.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Madhuri01:52 Rebranding Revvity as a healthcare company02:51 Advancements in sequencing and Revvity's projects, including newborn screening tests and clinical ultra-rapid sequencing12:29 Opportunities and challenges for newborn sequencing and global inequity in access17:46 Price of sequencing and data storage versus resequencing considerations21:10 Complexities and nuances of genomic data interpretation23:28 Rethinking data portability and storage across the lifespan26:00 Understanding penetrance and population genetics through lifelong sequencing27:36 Scaling genetic counseling to match advancements and the potential value of chatbots32:45 The promise of proteomics and translating Olink data to the clinic 34:31 Implementing polygenic risk scores in clinical management  37:12 Transitioning from academia to industry and insights into product development38:37 Closing remarksFind out moreRevvity (https://www.revvity.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

Episode Summary: In this deeply insightful episode, Dr. Nasha Winters is joined by renowned pediatric neurologist and researcher Dr. Richard Frye. With decades of experience and hundreds of peer-reviewed publications, Dr. Frye shares his groundbreaking work in autism spectrum disorder, particularly its links to mitochondrial dysfunction, neuroinflammation, and metabolic abnormalities.You'll learn how Dr. Frye's clinical and lab research is reshaping the narrative around autism—from a strictly genetic and behavioral model to a more hopeful, treatable biomedical framework.They dive into:The mitochondrial abnormalities often present in children with autismThe role of oxidative stress, folate transport issues, and methylationWhy nutrition and prenatal health matter more than everHow treatments like leucovorin, B12, CoQ10, and lifestyle changes can support better outcomesThe promising intersection of microbiome therapy, metabolic testing, and real-world clinical careThis is a must-listen for clinicians, caregivers, and anyone passionate about innovative approaches to autism care.Guest Bio:Dr Frye is a Harvard trained Child Neurologist who received both an MD and PhD from Georgetown University. Dr. Frye is a national leader in autism spectrum disorder (ASD) research, particularly metabolic disorders, and has authored over 300 publications. He has developed the Metabolic Learning Resource which has recently released The Folate Fix. He is President and Chief Scientific Officer of the Autism Discovery and Treatment Foundation, Chief Medical Officer of the Neurological Health Foundation, Director of Research and Neurologist at the Rossignol Medical Center.

Congressman Glenn Grothman from Wisconsin sheds light on the pressing issues surrounding immigration and judicial reform. Grothman discusses the alarming trend of unaccompanied migrant children going missing and criticizes the Democratic Party's stance on illegal immigration. He also addresses the challenges within the judiciary, highlighting concerns about radical judges and the impact of their decisions on American law. Additional interview with Dr. Peter McCullough, Chief Scientific Officer at The Wellness Company, who sounds the alarm on the rise of autism rates in America, as highlighted by HHS Secretary RFK Jr. and supported by new data. Finally, Senior policy analyst Andrés Martínez-Fernández from the Heritage Foundation provides insights on President Trump's recent meeting with El Salvador's President Nayib Bukele, focusing on their agreement to address the challenges of illegal immigration and criminal activity in the U.S.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, Dr. Scott Sigman sits down with Sarah Mayes, Ph.D., Chief Scientific Officer and Co-founder of Alafair Biosciences, and Dr. Eric Giza, Professor of Orthopaedic Surgery, Chief, Foot & Ankle Service, Co-Director, UC Davis/Reno Foot & Ankle Fellowship Head Team Physician, Sacramento Republic FC, UC Davis Department of Orthopaedic Surgery,  to discuss the journey behind VersaWrap Hydrogel Sheet. From its humble beginnings in a university lab to becoming an innovative solution for tendon and nerve protection, VersaWrap is redefining soft tissue healing. Sarah shares the entrepreneurial hurdles of bringing a medical device to market, while Dr. Giza provides a surgeon's perspective on how this cutting-edge product is impacting patient outcomes.

Dr. Keshav K. Singh is the Joy and Bill Harbert Endowed Chair and Professor of Genetics, Dermatology and Pathology at the University of Alabama at Birmingham. He is also the founding Editor-in-Chief of the Mitochondrion Journal. In addition, Keshav is the founder and Chief Scientific Officer of the company Yuva Biosciences. Research in Keshav's lab focuses on how to reverse aging and diseases like cancer that are associated with aging. Mitochondria are relevant for all of the hallmarks of aging, including things like changes in epigenetic regulation, genomic instability, and communication problems between cells. He is working to better understand the intricacies of how mitochondria work and how they can be targeted or leveraged to improve health. Outside of work, Keshav enjoys flying kites on the beach, traveling, and painting. In particular, he gets creative painting all different kinds of mitochondria, and this is a great outlet for him when experiments aren't working in the lab. Keshav began his studies in India, earning his Bachelor of Science degree in microbiology from Rohilkhand University and his Master of Science from G.B. Pant University of Agriculture and Technology. Next, he moved to Australia and was awarded his Ph.D. in Marine Biology from the University of Wollongong. Keshav then conducted postdoctoral research at Harvard University before joining the faculty at Johns Hopkins University School of Medicine. He later moved to the Roswell Park Comprehensive Cancer Center and served as Distinguished Professor of Oncology. Next, he joined the faculty at the University of Alabama at Birmingham where he is today. He is a Fellow of the Royal Society of Medicine and a member of Sigma Xi (The Scientific Research Honor Society). He has been recognized as one of the Innovation Heroes by Newsweek, and Yuva Biosciences was the recipient of the "Company of the Year - Innovation and Excellence into Mitochondrial Science" award at the Indian Icon Awards. In our interview, Keshav shares more about his life and science.

EP 205: Catharine Arnston, founder and Chief Scientific Officer of ENERGYbits, is back for another fascinating conversation—this time focused on women's health, hormones, and the power of algae. We dive into how spirulina and chlorella support mitochondrial function, balance hormones, and deliver potent antioxidant benefits, all grounded in decades of research. Catharine's passion for algae began when her sister fell ill, sparking a journey that led to the creation of ENERGYbits. Her deep knowledge and infectious enthusiasm make this a must-listen for anyone curious about how a simple, sustainable superfood can make a big impact. Check Out ENERGYbits | Click Here & use code DRTYNA for 20% off Topics Discussed:  How does algae support women's hormonal health and balance? What are the benefits of spirulina and chlorella for mitochondrial function? Can algae help with symptoms of perimenopause and menopause? Why is algae considered one of the most nutrient-dense superfoods? How do antioxidants in algae improve overall health and energy levels? On This Episode We Cover:  00:00:00 - Introduction  00:02:20 - Manufacturing process  00:04:22 - Different types of algae  00:06:37 - Manufacturing process 00:12:49 - Vegan collagen  00:14:43 - Mitochondrial health & estrogen  00:19:32 - Perimenopause 00:26:11 - Women's aging & hormone health  00:28:49 - Estrogen levels  00:34:55 - Dr. Tyna's experience with ENERGYbits  00:38:04 - Carnivore diet & chlorophyll  00:40:50 - Red light  00:45:43 - B Vitamins & decision fatigue  00:47:31 - Constipation  00:49:53 - Aging and finding joy  00:56:04 - Testimonials  Further Listening:  EP. 139: Algae 101 | Catharine Arnston of Energy Bits Hormones Playlist Sponsored By: ENERGYbits | Click Here & use code DRTYNA for 20% off Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

What if the key to reversing chronic disease, slowing cognitive decline, and boosting energy lies in the tiny powerhouses inside your cells—and we've finally found a way to protect them? We know mitochondria power our cells, but did you know they also create oxidative stress as they generate energy? Protecting mitochondrial health is critical—but most antioxidants can't reach inside the mitochondria where protection is needed most—until now. MitoQ, a scientifically advanced, mitochondria-targeted antioxidant developed by visionary researchers in New Zealand penetrates mitochondria up to 90%, offering protection where it's needed most. In this episode with Dr. Siobhan Mitchell, we dive into how MitoQ is transforming the way we tackle chronic disease, inflammation, and cognitive decline. From improving heart health to supporting brain function, MitoQ is changing the game. It's something I'm using personally and recommending to most of my patients. Listen in to discover how this powerful tool can help you support your patients at the cellular level—before symptoms even appear. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr Siobhan Mitchell, PhD., MitoQ Chief Scientific Officer Email: smitchell@mitoq.com Holding a PhD in neuroscience from SUNY Albany, Siobhan Mitchell has also completed a post-doctoral fellowship on brain aging at the University of Washington. She has over 15 years of clinical research experience, seven patents on mood and cognitive food products, and has authored over 50 papers on aging, brain health, nutrition, metabolic health and more. With a personal passion for brain aging research, Siobhan has worked on metabolic and skin health, appetite, sports physiology and of cellular health –which she now focuses on as the Chief Scientific Officer for research-backed cellular health company, MitoQ – creators of the world's first mitochondria-targeted antioxidant. THANKS TO OUR SPONSOR MitoQ: https://www.mitoQ.com/partner CustomerService@mitoq.com OFFER FOR NEW FRONTIERS LISTENERS Practitioners - Sign up to become a MitoQ Partner, access wholesale rates, and Unlock Cellular Health for your Patients by going to https://www.mitoq.com/partner CONNECT WITH DrKF Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, makers of NTFactor.

Dr. Drew is LIVE in Washington, DC, interviewing members of the Trump admin team including Sec. Robert F. Kennedy Jr, Karoline Leavitt, May Mailman, Sec. Linda McMahon. He's joined by special guest Dr. Peter McCullough. Dr. Peter McCullough is an internist, cardiologist, epidemiologist, and the Chief Scientific Officer at The Wellness Company. As an expert on cardiovascular medicine with over 30 years of experience, Dr. McCullough has spoken widely about the heart-related risks of mRNA. He is the co-author of The Courage To Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex. Follow Dr. McCullough at https://x.com/P_McCulloughMD and learn more at https://PeterMcCulloughMD.com Dr. Stephanie Venn-Watson is a co-founder of Seraphina Therapeutics. She holds a Doctor of Veterinary Medicine from Tufts University, a Master of Public Health from Emory University, and completed a National Research Council Associateship with the Armed Forces Medical Intelligence Center. As a Technical Agent for DARPA and researcher with the U.S. Navy Marine Mammal Program, she discovered C15:0's role in preventing Cellular Fragility Syndrome. This led her to co-found Seraphina Therapeutics, developing the fatty15 supplement. Find more at https://drdrew.com/fatty15 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Skin Anarchy, we sit down with Dr. Jérémie Soeur, Chief Scientific Officer, and Jennifer Hessel, General Manager of North America at Cellcosmet, to explore how cutting-edge research is redefining skincare. With a science-first approach, Cellcosmet is setting new standards in microbiome support, peptide technology, and cellular rejuvenation.Dr. Soeur explains how Cellcosmet's CytoPEP™ technology harnesses over 5,000 peptides, proteins, amino acids, and enzymes to target multiple skin-aging pathways. Unlike brands that rely on isolated ingredients, Cellcosmet's approach activates a network of biological functions to restore skin vitality. Their CellControl™ method ensures the peptides retain their structure and effectiveness throughout formulation, a step often overlooked in traditional skincare.Jennifer Hessel highlights the importance of microbiome research, explaining how Cellcosmet sequences bacteria before and after product use to measure its real impact on skin health. Their formulations not only nourish the microbiome but also protect against environmental stressors, making them a true game-changer in skincare.What sets Swiss skincare apart? Stringent quality control. Cellcosmet follows some of the world's strictest regulations, maintaining 100 times lower microbial contamination levels than standard beauty products, ensuring pharmaceutical-grade purity.As skincare personalization continues to evolve, Cellcosmet is pioneering the future—using microbiome sequencing and epigenetic research to develop tailored solutions for individual skin needs.Tune in to hear how science is driving the next era of beauty and why Cellcosmet is revolutionizing the way we think about skincare.SHOP Cellcosmet and use code SAcellcosmet15 for 15% off your first purchase!To learn more about Cellcosmet, visit their website and social media. Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.